Age-Related Molecular Degeneration Market Report 2023: R&D Consistency Drives Sector Growth

The global age-related molecular degeneration market is currently valued at US$ 11.28 Million in 2023 and is anticipated to expand at a CAGR of 7%. Owing to the technological advances in healthcare the market is likely to propel to US$22.19 Million by 2033.

The increasing prevalence of AMD and a strong product pipeline are anticipated to be the major drivers for the growth of age-related molecular degeneration market. According to the WHO, around 196 million people were affected by age-related macular degeneration globally in 2020, including over 10.4 million moderate-to-severe vision impairment cases.

Globally, advanced age-related macular degeneration is the primary factor in irreversible blindness and visual impairment. As a result, the market for age-related macular degeneration is anticipated to experience significant growth over the forecast period.

Most severe eye conditions are rising globally, and vision loss is becoming a significant public health issue and increase in the prevalence of the retinal disorder in many developed and developing nations drive market growth. The wet age-related macular degeneration segment is the highest contributor to the market and is expected to grow at a CAGR of 6.9% over the forecast period.

North America dominates the age-related molecular denegation market due to the presence of key market players' presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market's growth in the region.

The significant R&D investments in Europe abode well for market growth. Growing awareness of macular degeneration in Asia-Pacific and the presence of key market players, and the rising elderly population in Japan all point to significant growth in the Japanese market for age-related molecular degeneration.

Competitive Landscape

Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Biogen, Samsung Bioepis, Ophthotech Corporation are some of the key players in the age related molecular degeneration industry.

Browse More@ https://www.futuremarketinsights.com/reports/age-related-macular-degeneration-market

More Valuable Insights Available

FMI, in its new offering, presents an unbiased analysis of the age related molecular degeneration market, presenting historical demand data (2018-2022) and forecast statistics for the period of 2023-2033.

The study divulges essential insights on the age related molecular degeneration market by Product (Eylea, Lucentis, Beovu), By Disease Type (Wet AMD, Dry AMD), By Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy) by Region - Global Forecast 2023-2033

Comments

Post a Comment

Popular posts from this blog

Portable Oxygen Concentrators Market | Innovative and Technological Advancement

Image
The global  portable oxygen concentrators market  is anticipated to witness lucrative growth opportunities over the forecast period from 2022 and 2032, with a phenomenal CAGR of 10.1%. The market is expected to enjoy a valuation of US$ 1.9 Billion by the end of the year 2022 and surpass a projection of US$ 5.0 Billion by the year 2032. According to the Future Market Insights historical analysis, the pulse flows portable oxygen concentrators were leading the market with a share of about 67.7% in the year 2021, within the global market. In the year 2021, the market value for portable oxygen concentrators was around 54.8% of the overall US$ 3.5 Billion of the global oxygen concentrators market. Portable oxygen concentrators supply oxygen to those patients who are suffering from respiratory diseases such as chronic obstructive pulmonary disease. In this process, nitrogen and oxygen are separated from the air in the environment with the help of the concentrator which then discards ...
Read more

Helicobacter Pylori Infections Treatment Market Research and Analysis 2023 to 2033

Image
The global helicobacter pylori infections treatment market is predicted to reach US$ 638.3 Million in 2023, with a compound annual growth rate (CAGR) of 7.04% anticipated from 2023 to 2033, reaching US$ 1,260 Million. The spread of such infections can be attributed to a number of factors, including a lack of adequate water supply, poor sanitation, a large population, and poor personal hygiene. One of the factors influencing the Helicobacter pylori diagnostics market's growth is increased awareness of H. pylori infections in the cohort. Antibiotic availability and affordability, as well as quicker processing times, will boost antibiotic use and the need for pre and post-surveillance tests. Furthermore, rising H. pylori infection rates, the need for early symptom diagnosis, and technological advances in diagnostic methods are expected to fuel overall growth over the forecast period. The key drivers of the industry are the increasing prevalence of communicable diseases and rising pub...
Read more

Pediatric Clinical Trials Market size is set to Grow at a Remarkable Pace by 2032

Image
During the forecast period 2022 to 2032, the global pediatric clinical trials market  is expected to grow at a value of 5.3%, according to Future Market Insights. In 2022, this market was predicted to have a global valuation of US$ 15.8 Billion, and is expected to reach a sum of US$ 26.47 Billion by 2032. The market is going to face increasing demand owing to the increase of pediatric chronic and genetic diseases all across the world. The growing need for novel vaccines and biopharmaceuticals to treat infectious diseases such as measles, polio, tuberculosis, rubella, influenza, mumps, whooping cough, malaria, chickenpox, and staphylococcus pharyngitis is expected to drive market growth. At the same time, diabetes is a big worry among today's children. The market is being driven by rising parental awareness of children clinical trials for severe infections and chronic diseases, as well as a large number of CROs doing pediatric research. In 2021, the onc...
Read more